logo-loader

Humanigen chosen by National Institute of Health's upcoming coronavirus clinical trial

Published: 15:40 31 Jul 2020 BST

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial.

Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’ (NIAID) Big Effect Trial (BET) in patients hospitalized with COVID-19.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 52 minutes ago